pre-IPO PHARMA

COMPANY OVERVIEW

FluGen, Inc. is a clinical stage vaccine company focused on improving the breadth and effectiveness of influenza vaccines. The Company’s technology comes from the laboratory of Dr. Yoshihiro Kawaoka at the University of Wisconsin, Madison. It’s lead product candidate, RedeeFlu™ is a universal flu vaccine which is based on the knowledge that a natural or “wild-type” flu infection prevents people from being infected in subsequent years.


LOCATION

  • Madison, WI, USA

  • THERAPEUTIC AREAS

  • Infectious Disease

  • WEBSITE

    https://flugen.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Nov 9, 2022

    New Data Published in the Journal of Infectious Diseases Demonstrate FluGen's M2SR Vaccine Candidate Substantially Enhances Mucosal and Serum Antibodies Against Drifted Influenza Strains


    Sep 7, 2022

    FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years


    Jun 22, 2022

    FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults


    Jan 5, 2022

    FluGen to Present at the 40th Annual J.P. Morgan Healthcare Conference


    Sep 7, 2021

    FluGen to Present at Baird's 2021 Global Healthcare Conference


    For More Press Releases


    Google Analytics Alternative